Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) EBIT Margin: 2015-2020

Historic EBIT Margin for Outlook Therapeutics (OTLK) over the last 6 years, with Sep 2020 value amounting to 52,617.92%.

  • Outlook Therapeutics' EBIT Margin rose 5283474.00% to 52,617.92% in Q3 2020 from the same period last year, while for Sep 2020 it was 2,097.42%, marking a year-over-year increase of 254302.00%. This contributed to the annual value of 2,271.27% for FY2024, which is 17243.00% up from last year.
  • Latest data reveals that Outlook Therapeutics reported EBIT Margin of 52,617.92% as of Q3 2020, which was up 1,865.00% from 2,677.76% recorded in Q2 2020.
  • Outlook Therapeutics' 5-year EBIT Margin high stood at 52,617.92% for Q3 2020, and its period low was -5,870.30% during Q4 2016.
  • Over the past 3 years, Outlook Therapeutics' median EBIT Margin value was -884.97% (recorded in 2018), while the average stood at 4,623.81%.
  • As far as peak fluctuations go, Outlook Therapeutics' EBIT Margin tumbled by 422,056bps in 2016, and later soared by 5,283,474bps in 2020.
  • Outlook Therapeutics' EBIT Margin (Quarterly) stood at -5,870.30% in 2016, then surged by 545,836bps to -411.95% in 2017, then slumped by 54,884bps to -960.78% in 2018, then soared by 233,012bps to 1,369.33% in 2019, then surged by 5,283,474bps to 52,617.92% in 2020.
  • Its EBIT Margin was 52,617.92% in Q3 2020, compared to 2,677.76% in Q2 2020 and 971.59% in Q1 2020.